Phathom Pharmaceuticals, Inc.
PHAT
NASDAQ·Healthcare·Biotechnology·Mkt cap $768.6M
$9.50
▲ +4.97%
P/E
-7.42
Mkt Cap
$768.6M
52-Wk Range
$8.21–$18.31
52-Week Range
$8.21 - $18.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 23.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Novel P-CAB mechanism of action with superior acid suppression vs. traditional PPIs
- Exclusive North American and European rights to vonoprazan with strong patent protection
- Advanced clinical development stage with Phase III trials demonstrating efficacy and safety
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Strong growth ahead
Successful Phase III trial completion and FDA approval for GERD and H. pylori indications
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Weak
-5.0% over 3m
Quality
Excellent
High-growth business (110% revenue growth, 83% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying PHAT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of -$0.21 vs -$0.18 consensus (-19.6% surprise). Revenue of $74.3M vs $73.2M expected (+1.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-19.6%
Revenue trend · last 8Q
—
—
—
+439%
+203%
+94%
+104%
+88%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$16.4M
$29.7M
$28.5M
$39.5M
$49.5M
$57.6M
$58.3M
$74.3M
Margins · last 8Q
Gross
79.7%
Operating
-5.3%
Profit
0.0%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Jul 31, 2026
vs Industry
How PHAT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related